A systems approach to designing effective clinical trials using simulations

Circulation

Volumn 127, Issue 4, 2013, Pages 517-526

  Fusaro, Vincent A ^a   Patil, Prasad ^b   Chi, Chih Lin ^a   Contant, Charles F ^c   Tonellato, Peter J ^a  

^a Harvard Medical School Center for Biomedical Informatics   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Bioinformatics; Clinical trials; Individualized medicine; Modeling; Pharmacogenetics; Simulations; Warfarin

Indexed keywords

COUMAGEN; UNCLASSIFIED DRUG; WARFARIN;

ALGORITHM; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); COMPUTER SIMULATION; OUTCOME ASSESSMENT; PHARMACOGENETICS; PRIORITY JOURNAL; STUDY DESIGN;

ANIMALS; ANTICOAGULANTS; COMPUTER SIMULATION; DRUG EVALUATION, PRECLINICAL; HUMANS; MODELS, THEORETICAL; PHARMACOGENETICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SYSTEMS THEORY; THROMBOSIS; WARFARIN;

EID: 84873180434     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.112.123034     Document Type: Article

References (34)

1. Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, Limdi NA, Page D, Roden DM, Wagner MJ, Caldwell MD, Johnson JA. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009;360:753-764.
2. Carlquist JF, Anderson JL. Using pharmacogenetics in real time to guide warfarin initiation: a clinician update. Circulation. 2011;124:2554-2559.
3. Hamberg AK, Wadelius M, Lindh JD, Dahl ML, Padrini R, Deloukas P, Rane A, Jonsson EN. A pharmacometric model describing the relationship between warfarin dose and INR response with respect to variations in CYP2C9, VKORC1, and age. Clin Pharmacol Ther. 2010;87:727-734.
4. Gage BF, Eby C, Johnson JA, Deych E, Rieder MJ, Ridker PM, Milligan PE, Grice G, Lenzini P, Rettie AE, Aquilante CL, Grosso L, Marsh S, Langaee T, Farnett LE, Voora D, Veenstra DL, Glynn RJ, Barrett A, McLeod HL. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther. 2008;84:326-331.
5. Anderson JL, Horne BD, Stevens SM, Grove AS, Barton S, Nicholas ZP, Kahn SF, May HT, Samuelson KM, Muhlestein JB, Carlquist JF; Couma-Gen Investigators. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation. 2007;116:2563-2570. (Pubitemid 350179221)
6. Gage BF, Eby C, Milligan PE, Banet GA, Duncan JR, McLeod HL. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost. 2004;91:87-94. (Pubitemid 38111225)
7. Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, Wood P, Kesteven P, Daly AK, Kamali F. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood. 2005;106:2329-2333. (Pubitemid 41510803)
8. Fennerty A, Dolben J, Thomas P, Backhouse G, Bentley DP, Campbell IA, Routledge PA. Flexible induction dose regimen for warfarin and prediction of maintenance dose. BMJ. (Clin Res Ed). 1984;288:1268-1270. (Pubitemid 14117132)
9. Gedge J, Orme S, Hampton KK, Channer KS, Hendra TJ. A comparison of a low-dose warfarin induction regimen with the modified Fennerty regimen in elderly inpatients. Age Ageing. 2000;29:31-34. (Pubitemid 30055060)
10. Kovacs MJ, Rodger M, Anderson DR, Morrow B, Kells G, Kovacs J, Boyle E, Wells PS. Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism. A randomized, double-blind, controlled trial. Ann Intern Med. 2003;138:714-719.
11. Perlstein TS, Goldhaber SZ, Nelson K, Joshi V, Morgan TV, Lesko LJ, Lee JY, Gobburu J, Schoenfeld D, Kucherlapati R, Freeman MW, Creager MA. The Creating an Optimal Warfarin Nomogram (CROWN) Study. Thromb Haemost. 2012;107:59-68.
12. Wilson SE, Costantini L, Crowther MA. Paper-based dosing algorithms for maintenance of warfarin anticoagulation. J Thromb Thrombolysis. 2007;23:195-198. (Pubitemid 46564119)
13. Dickinson GL, Lennard MS, Tucker GT, Rostami-Hodjegan A. The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies-CYP2C9 and warfarin as an example. Br J Clin Pharmacol. 2007;64:14-26. (Pubitemid 46934416)
14. Hamberg AK, Dahl ML, Barban M, Scordo MG, Wadelius M, Pengo V, Padrini R, Jonsson EN. A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therap y. Clin Pharmacol Ther. 2007;81:529-538. (Pubitemid 46452304)
15. Choi JR, Kim JO, Kang DR, Yoon SA, Shin JY, Zhang X, Roh MO, Hong HJ, Wang YP, Jo KH, Lee KS, Yun HJ, Oh YS, Yoo KD, Jeon HG, Lee YS, Kang TS, Park HJ, Chung MW, Kang JH. Proposal of pharmacogenetics-based warfarin dosing algorithm in Korean patients. J Hum Genet. 2011;56:290-295.
16. Perini JA, Struchiner CJ, Silva-Assunção E, Santana IS, Rangel F, Ojopi EB, Dias-Neto E, Suarez-Kurtz G. Pharmacogenetics of warfarin: development of a dosing algorithm for Brazilian patients. Clin Pharmacol Ther. 2008;84:722-728.
17. Takeuchi F, Kashida M, Okazaki O, Tanaka Y, Fukuda S, Kashima T, Hosaka S, Hiroe M, Kimura S, Kato N. Evaluation of pharmacogenetic algorithm for warfarin dose requirements in Japanese patients. Circ J. 2010;74:977-982.
18. You JH, Wong RS, Waye MM, Mu Y, Lim CK, Choi KC, Cheng G. Warfarin dosing algorithm using clinical, demographic and pharmacogenetic data from Chinese patients. J Thromb Thrombolysis. 2011;31:113-118.
19. Zambon CF, Pengo V, Padrini R, Basso D, Schiavon S, Fogar P, Nisi A, Frigo AC, Moz S, Pelloso M, Plebani M. VKORC1, CYP2C9 and CY-P4F2 genetic-based algorithm for warfarin dosing: an Italian retrospective study. Pharmacogenomics. 2011;12:15-25.
20. Cavallari LH, Momary KM, Patel SR, Shapiro NL, Nutescu E, Viana MA. Pharmacogenomics of warfarin dose requirements in Hispanics. Blood Cells Mol Dis. 2011;46:147-150.
21. Caraco Y, Blotnick S, Muszkat M. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin Pharmacol Ther. 2008;83:460-470. (Pubitemid 351272635)
22. Huang SW, Chen HS, Wang XQ, Huang L, Xu DL, Hu XJ, Huang ZH, He Y, Chen KM, Xiang DK, Zou XM, Li Q, Ma LQ, Wang HF, Chen BL, Li L, Jia YK, Xu XM. Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients. Pharmacogenet Genomics. 2009;19:226-234.
23. Robinson KA, Goodman SN. A systematic examination of the citation of prior research in reports of randomized, controlled trials. Ann Intern Med. 2011;154:50-55.
24. Salinger DH, Shen DD, Thummel K, Wittkowsky AK, Vicini P, Veenstra DL. Pharmacogenomic trial design: use of a PK/PD model to explore warfarin dosing interventions through clinical trial simulation. Pharmacogenet Genomics. 2009;19:965-971.
25. Scheines R, Spirtes P, Glymour C, Meek C, Richardson T. The tetrad project: Constraint based aids to causal model specification. Multivariate Behav Res. 1998;33:65-117. (Pubitemid 128353347)
26. Bauer L. Applied Clinical Pharmacokinetics. New York, NY: The Mc-Graw-Hill Companies; 2001.
27. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York, MY: Marcel Dekker, Inc; 1982.
28. Soetaert K, Petzoldt T, Setzer WR. Solving differential equations in r: Package desolve. J Stat Softw. 2010;33.
29. R Development Core Team. R: A Language and Environment for Statistical Computing. 2011.
30. Fusaro VA, Patil P, Gafni E, Wall D P, Tonellato PJ. Biomedical cloud computing with Amazon Web Services. PLoS Comput Biol. 2011;7:e1002147.
31. Fienberg SE. An iterative procedure for estimation in contingency tables. Ann Math Statist. 1970;41:907-917.
32. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-891.
33. Fleming TR, Emerson SS. Evaluating rivaroxaban for nonvalvular atrial fibrillation-regulatory considerations. N Engl J Med. 2011;365:1557-1559.
34. Mega JL. A new era for anticoagulation in atrial fibrillation. N Engl J Med. 2011;365:1052-1054.